Articles

Poll

Podcasts

Slideshows

Videos

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Combination therapy with navepegritide and lonapegsomatropin has demonstrated its efficacy in improving mean annualized growth velocity in pediatric patients.

Ascendis Reports 78-Week Data From COACH Trial for Achondroplasia

New Drug Applications and key trial readouts punctuated July for endocrinology, with treatments for hypocalcemia, diabetes, and more.

5 Endocrinology Headlines You Missed in July 2026

If approved, encaleret will be the first treatment specifically indicated for this underrepresented patient population.

FDA Accepts NDA for Encaleret for Autosomal Dominant Hypocalcemia Type 1

FDA accepted Camurus’ resubmitted CAM2029 application for acromegaly, with a target action date of December 18, 2026.

FDA Accepts Resubmitted CAM2029 NDA for Acromegaly

Data from the ongoing open-label extensions of PATHFNDR-1 and PATHFNDR-2, presented at ENDO 2026, highlight the drug’s efficacy in reducing IGF-1.

2-Year Paltusotine Data Confirms Efficacy, Safety for Acromegaly in Treatment-Naïve and SRL-Treated Patients

Fechner discusses the 2-year data from an open-label extension of the CAHtalyst Pediatric study, maintaining substantial glucocorticoid dose lowering.

Crinecerfont Maintains Improvements in Pediatric CAH at 2 Years, With Patricia Fechner, MD

Shahla discusses a recent real-world study analyzing the clinical outcomes of patients prescribed paltusotine after its September 2025 approval.

Real-World Data Reinforces Paltusotine’s IGF-1 Reductions in Acromegaly, With Leena Shahla, MD

Bacino highlights the recently approved treatment’s safety data and emphasizes the likelihood of increased adherence due to longer intervals between administration.

Once-Weekly Navepegritide Safe and Efficacious for Achondroplasia, With Carlos Bacino, MD

2025 featured multiple advancements in women's health aimed at enhancing treatment options and awareness.

From GSM guidance to HRT reform: A landmark year for women’s health

Catch up on the most impactful headlines in hormonal disorders from all of 2025 with our Year in Review.

Hormonal Disorders